Latest Director Participation News

Stavely Minerals has locked in A$4 million through a heavily oversubscribed placement, backing its upcoming Thursday’s Gossan Scoping Study and exploration programs. The raise underscores investor confidence ahead of key milestones.

Megado Minerals Limited has secured A$1.65 million through a placement and director subscription to fund drilling and exploration at its Iberian Copper and Alpartir Silver-Copper projects in Northern Spain.

AuMEGA Metals Limited has launched a prospectus for a dual-tranche capital raising totalling approximately C$23.7 million, subject to shareholder approval, aimed at advancing its exploration programs in Newfoundland and Labrador, Canada.

Kali Metals Limited (ASX:KM1) has finalised its Tranche 2 Placement, issuing 527,778 shares at A$0.18 each and raising approximately A$95,000 following shareholder approval.

Ardea Resources has successfully raised $340,000 through a Shareholder Purchase Plan following a $5 million placement, demonstrating shareholder confidence despite ongoing geopolitical tensions.

Clara Resources pivots exclusively to its Mareeba Gold Project in North Queensland, securing $1.1 million in fresh capital and renewing its board to drive exploration in a historically rich but underexplored gold province.

Count Limited has successfully raised $35.9 million through an institutional placement to partially fund its acquisition of Oracle Group Ltd, while also launching a $5 million Share Purchase Plan for existing shareholders.

Red Sky Energy is set to raise up to $5.2 million through a placement and rights issue to fund its participation in a Santos-operated drilling program in South Australia’s Innamincka Dome. The capital raise aims to accelerate near-term production and cash flow from existing and new wells.

Chariot Resources has raised A$2.1 million through a share placement, attracting institutional and sophisticated investors to back its expanding lithium projects in the US and Nigeria. The placement includes free attaching options, pending shareholder approval.

EVE Health Group has increased its placement funding to $1.3 million, backed by a cornerstone investor with pharmaceutical expertise, advancing its reformulated drug programs targeting billion-dollar global markets.

Findi Limited has extended the closing date of its offer to 19 March 2026 and updated details following a $25 million institutional placement. The company’s share capital structure and financial position have been revised, with key changes including director participation and lead manager incentives.

EVE Health Group has raised $0.9 million to advance its pharmaceutical reformulation programs targeting global markets worth over US$30 billion. The funding will support development of improved delivery technologies for medicines nearing patent expiry.